Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates

Journal of Clinical Microbiology

Volumn 46, Issue 10, 2008, Pages 3459-3464

  Mphahlele, Matsie ^a,b   Syre, Heidi ^a,e   Valvatne, Håvard ^a   Stavrum, Ruth ^a,e   Mannsåker, Turid ^c   Muthivhi, Tshilidzi ^b   Weyer, Karin ^b   Fourie, P Bernard ^d   Grewal, Harleen M S ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^c NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^d MRC Building   (South Africa)

^e HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDASE; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDASE; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE MUTATION; GENE SEQUENCE; GENOTYPE; INTERSPERSED REPEAT; LUNG TUBERCULOSIS; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PNCA GENE; POINT MUTATION; PRIORITY JOURNAL; RADIOMETRY; SOUTH AFRICA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMIDOHYDROLASES; AMINO ACID SUBSTITUTION; ANTITUBERCULAR AGENTS; DNA FINGERPRINTING; DNA, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GENOTYPE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION, MISSENSE; MYCOBACTERIUM TUBERCULOSIS; POINT MUTATION; PYRAZINAMIDE; SEQUENCE ANALYSIS, DNA; SOUTH AFRICA; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

CORYNEBACTERINEAE; MYCOBACTERIUM TUBERCULOSIS;

EID: 53649111744     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.00973-08     Document Type: Article

References (25)

1. Brudey, K., J. R. Driscoll, L. Rigouts, W. M. Prodinger, A. Gori, S. A. Al-Hajoj, C. Allix, L. Aristimuno, J. Arora, and V. Baumanis. 2006. Mycobacterium tuberculosis complex genetic diversity: mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiology. BMC Microbiol. 6:23.
2. Butler, W. R., and J. O. Kilburn. 1983. Susceptibility of Mycobacterium tuberculosis to pyrazinamide and its relationship to pyrazinamidase activity. Antimicrob. Agents Chemother. 24:600-601.
3. Dale, J. W., D. Brittain, A. A. Cataldi, D. Cousins, J. T. Crawford, J. Driscoll, H. Heersma, T. Lillebaek, T. Quitugua, N. Rastogi, R. A Skuce, C. Sola, D. van Soolingen, and V. Vincent. 2001. Spacer oligonucleotide typing of bacteria of the Mycobacterium tuberculosis complex: recommendations for standardized nomenclature. Int. J. Tuberc. Lung Dis. 5:216-219.
4. Davies, A. P., O. J. Billington, T. D. McHugh, D. A. Mitchison, and S. H. Gillespie. 2000. Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility testing with Mycobacterium tuberculosis. J. Clin. Microbiol. 38:3686-3688.
5. Frothingham, R., and W. A. Meeker-O'Connell. 1998. Genetic diversity in the Mycobacterium tuberculosis complex based on variable numbers of tandem DNA repeats. Microbiology 144:1189-1196.
6. Groenen, P. M., A. E. Bunschoten, D. van Soolingen, and J. D. van Embden. 1993. Nature of DNA polymorphism in the direct repeat cluster of Mycobacterium tuberculosis, application for strain differentiation by a novel typing method. Mol. Microbiol. 10:1057-1065.
7. Heifets, L., and P. Lindholm-Levy. 1992. Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations. Am. Rev. Respir. Dis. 145:1223-1225.
8. Kam, K. M., W. C. Yip, W. L. Tse, K. L. Wong, K. T. Lam, K. Kremer, B. K. Au, and D. van Soolingen. 2005. Utility of mycobacterial interspersed repetitive unit typing for differentiating multidrug-resistant Mycobacterium tuberculosis isolates of the Beijing family. J. Clin. Microbiol. 43:306-313.
9. Louw, G. E., R. M. Warren, P. R. Donald, M. B. Murray, M. Bosman, P. D. van Helden, D. B. Young, and T. C. Victor. 2006. Frequency and implications of pyrazinamide resistance in managing previously treated tuberculosis patients. Int. J. Tuberc. Lung Dis. 10:802-807.
10. McDermott, W., and R. Tompsett. 1954. Activation of pyrazinamide and nicotinamide in acidic environment in vitro. Am. Rev. Respir. Dis. 70:748-754.
11. Mitchison, D. A. 1985. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 66:219-225.
12. Morlock, G. P., J. T. Crawford, W. R. Butler, S. E. Brim, D. Sikes, G. H. Mazurek, C. L. Woodley, and R. C. Cooksey. 2000. Phenotypic characterization of pncA mutants of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 44:2291-2295.
13. Portugal, I., L. Barreiro, J. Moniz-Pereira, and L. Brum. 2004. pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates in Portugal. Antimicrob. Agents Chemother. 48:2736-2738.
14. Ramaswamy, S., and J. M. Musser. 1998. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber. Lung Dis. 79:3-29.
15. Raynaud, C., M. A. Laneelle, R. H. Senaratne, P. Draper, G. Laneelle, and M. Daffe. 1999. Mechanisms of pyrazinamide resistance in mycobacteria: importance of lack of uptake in addition to lack of pyrazinamidase activity. Microbiology 145:1359-1367.
16. Scorpio, A., and Y. Zhang. 1996. Mutations in pncA, a gene encoding pyrazinamidase/ nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat. Med. 2:662-667.
17. Scorpio, A., P. Lindholm-Levy, L. Heifets, R. Gilman, S. Siddiqi, M. Cynamon, and Y. Zhang. 1997. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 4:540-543.
18. Siddiqi, S. H. 1989. BACTEC TB system, product and procedure manual. Becton Dickinson Diagnostic Instruments Systems, Towson, MD.
19. Stottmeier, K. D., R. E. Beam, and G. P. Kubica. 1967. Determination of drug susceptibility of mycobacteria to pyrazinamide in 7H10 agar. Am. Rev. Respir. Dis. 96:1072-1075.
20. Wayne, L. G. 1974. Simple pyrazinamidase and urease tests for routine identification of mycobacteria. Am. Rev. Respir. Dis. 109:147-151.
21. Weyer, K., J. Lancaster, J. Brand, M. van der Walt, and J. Levin. 2004. Survey of tuberculosis drug resistance in South Africa 2001-2002. Final report. MRC, Pretoria, South Africa. http://www.sahealthinfo.org/tb/natsurvey. pdf.
22. World Health Organization. 2008. Global tuberculosis control: surveillance, planning, financing. World Health Organization, Geneva, Switzerland. http: //www.who.int/tb/publications/global_report/2008/pdf/ fullreport.pdf.
23. World Health Organization/IUATLD. 2004. Antituberculosis drug resistance in the world. Third global report. World Health Organization, Geneva, Switzerland. http://www.who.int/tb/publications/who_htm_tb_2004_343/en/index. html.
24. Zhang, Y., A. Scorpio, H. Nikaido, and Z. Sun. 1999. Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. J. Bacteriol. 181:2044-2049.
25. Zignol, M., M. S. Hosseini, A. Wright, C. Lambregts-van Weezenbeek, P. Nunn, C. J. Watt, and B. G. Williams. 2006. Global incidence of multidrug-resistant tuberculosis. J. Infect. Dis. 194:479-485.